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Objective: This study aimed to describe the current status of lung cancer in Spain, 
including patient characteristics and in-hospital mortality, and to revise disease 
management and the direct medical costs of secondary care.  
Methods: A retrospective observational study was set to analyse anonymised primary and 
secondary care records of patients admitted with lung cancer in Spain between 2011 and 
2016. Data were obtained from the Primary Care Dataset and the Centralised Hospital 
Discharge Database. 
Results: Admissions files from 12,119 primary care and 113,574 secondary care patients 
were analysed. Only 21% of all patients were females, yet the number of female patients 
presented an increasing trend over the study period. Non-small-cell lung carcinoma 
represented 85.29% of all lung malignant neoplasms; metastatic or secondary malignant 
neoplasms were diagnosed in 76.66% of admissions. Other relevant comorbid conditions 
registered at the hospital level were hypertension, disorders of lipoid metabolism, diabetes 
mellitus and a history of tobacco use. In-hospital mortality was 22% over the study period 
and was associated with respiratory failure. Mean hospitalisation time was 9.57 days and 
most admissions were due to emergencies. The mean cost of secondary care per patient was 
€8,475, increasing significantly over the study period. Cost per patient was higher in those 
diagnosed with a squamous cell carcinoma. 
Conclusions: Preventive and early detection measures are recommended, continuing to 
focus on females. In parallel, a multidisciplinary approach could optimise patient journey 
considering the presence of disease comorbidities, although its role in lung cancer mortality 
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Worldwide, lung cancer is the most common cancer type, with an age-standardised 
incidence rate of 22.5 per 100,000 in 2018 [1]. Prevalence is significantly elevated in North 
America and Europe, being, in this last case, Hungary the country with the highest 
incidence rate for both males and females [2]. In Spain, lung cancer incidence rates are 42.1 
per 100,000 for males and 14.0 per 100,000 for females; lung cancer incidence has 
displayed a decreasing trend in males over the past decade, yet it remains as one of the 
principal causes of disability and mortality [2-4]. 
The lung cancer age-standardised mortality rate worldwide was 18.6 per 100,000 in 2018, 
similar to that in Spain, where the 5 year relative survival rate was only 13.5% between 
2010 and 2014 [1, 5]. Nevertheless, a decrease in mortality has been observed, presumably 
promoted by the decreasing smoking prevalence, reversing the increasing trend followed 
until the mid-nineties; still, for females, lung cancer mortality maintained the growing trend 
at least until 2012 [6, 7]. The differential incidence and mortality rates observed for females 
have been primarily related to variations in smoking habits, with studies indicating a higher 
smoking prevalence among Spanish teenage girls, when compared to boys, up to 2002 [8]. 
Tobacco smoke remains the principal factor in lung carcinogenesis, followed by indoor 
radon, a natural radioactive gas found in indoor environments [9, 10]. In addition, 
polymorphism in several chromosome regions (i.e. the cholinergic nicotine receptor genes) 
have been associated to lung cancer susceptibility, while less evidence has been found in 
association with the diet and alcohol consumption [11]. A clear understanding of the effect 
that these factors may have will be of utmost importance for the implementation of 
preventive policies.  
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On the other hand, the development of more efficient diagnostic and treatment models 
contributes to control cancer incidence and mortality. It has been challenging to advance in 
this direction due to the complexity of lung carcinoma at the molecular and histological 
level. In general terms, two main groups have been described based on tumour histology 
and prognosis: small-cell carcinoma (SCLC) and non-small-cell carcinoma (NSCLC) that 
represent about 85% and 15% of all lung cancers, respectively [12, 13]. In turn, NSCLCs 
are classified into adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large-cell 
carcinoma (LCC). Additionally, distinct genetic variants have influence in disease 
prognosis, including mutations in the epidermal growth factor receptor (EGFR) gene, the 
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) or the B-Raf Proto-Oncogene, 
Serine/Threonine Kinase (BRAF) [13].  
These elements, together with other patient characteristics and risk factors are relevant for 
the revision of preventive and treatment protocols, including the implementation of lung 
cancer screening programs via low-dose computed tomography (CT), which could provide 
significant benefits when applied to high-risk populations [14]. International consent in the 
generalised use of such screenings has not been reached; however, European experts 
recommend their application, following a risk stratification approach to be based on an 
accurate description of the population at risk [15]. In addition, the access to real-world 
evidence that reflects current practice from complementary observational prospective and 
retrospective studies is considered crucial to revise preventive and treatment protocols, and 
to develop adequate resource allocation strategies [16, 17]. 
Thus, the aim of this study was to describe the characteristics of patients with lung cancer 
in Spain and any factors that may play a role in lung cancer mortality, identify any temporal 
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tendencies and analyse patients’ use of medical resources and direct medical costs of 
secondary care. 
Methods 
Study setting and design  
Healthcare records of patients admitted with lung cancer in primary and specialised 
healthcare centres in Spain were analysed in a retrospective multicentre observational 
study. Data was obtained from the Primary Care Dataset and the Centralised Hospital 
Discharge Database via the Spanish Ministry of Health, two databases that compile data 
from private and public healthcare centres representative of all Spanish regions [18]. Data 
is codified at the centre or hospital level by specialised doctors by using the Spanish ICD 
codification guides made available to health professionals, and centres are responsible for 
data codification, evaluation and confidentiality. Each database is validated internally and 
subjected to periodic audits. In this process, errors and unreliable data are eliminated. Data 
inclusion was established to comprise most recent available data at the moment of the 
analysis, starting 1 Jan 2011 to 31 Dec 2016. 
Data extraction 
Records of admissions in which lung cancer was registered as the admission motive were 
petitioned and identified by means of the International Classification of Primary Care 
second edition (ICPC-2) and the 9th and 10th revisions of the International Statistical 
Classification of Diseases and Related Health Problems, clinical modification (ICD-9-CM 
and ICD-10-CM) codes. The corresponding ICD-9-CM and ICD-10-CM were used to 
identify lung cancer diagnoses and tumour location, and, when available, the International 
Classification of diseases for Oncology, third edition (ICD-O-3) was used to categorise 
tumour morphology (Table 1).  
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The Spanish Ministry of Health was in charge of data extraction, with any parameters 
identifying the medical history and health centres previously re-coded to avoid any access 
to identifying information in accordance with the principles of Good Clinical Practice and 
the Declaration of Helsinki. In such cases the Spanish legislation does not require patient 
consent and ethics committee approval according to the Law 14/2007, 3 July, on 
biomedical research, Spain [19]. Patients were not directly involved in the research or the 
study design. 
Study variables 
Both databases register information about the patient and admission details. Primary care 
data includes patients’ sex, age, income level and employment status, centre location, date 
of admission and admission motive. The secondary care database registers patients’ sex and 
age, hospital location, date of admission, type of admission, date of discharge, type of 
discharge (including death), service to discharged the patient, length of stay, readmission 
rate, admission motive, secondary diagnoses registered during the admission, tumour 
morphology (codified with the International Classification of diseases for Oncology (ICD-
O-3) codes), medical procedures performed and cost of the admission. 
Data analysis 
Admission motive data was used to identify patients with lung cancer. Primary care records 
were analysed to determine patient characteristics and socioeconomic profile; all secondary 
care admission records were used to evaluate patient journey upon hospitalisation: nature of 
the admission, services to discharge the patient, days of stay and medical procedures. The 
analysis of patient characteristics via single-patient data was based on the first admission 
registered per patient due to lung cancer. 
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Direct medical costs of secondary care were estimated by using the admission cost 
determined in the database, based on the standardised average expenses of admissions and 
medical procedures determined by the Spanish Ministry of Health. This calculation 
included all expenses related treatment (examination, medication and surgery), nutrition, 
costs associated to personnel, medical equipment and resources. 
To describe the patient population patients were grouped according to tumour histology. A 
descriptive univariate analysis was done. Frequencies and percentages are presented for 
dichotomous variables and mean and standard deviation or error were calculated for 
parametric quantitative variables. Odd ratios (OR) with 95% confidence interval (CI) were 
used to assess the association of secondary conditions with in-hospital mortality, with the 
group of patients non-deceased during the hospitalisation as the reference group. Two-
tailed T-student or one-way analysis of variance were used according to data distribution 
and two-sample Z tests were used to test for differences in sample proportions, with a 
p<0.05 considered statistically significant in all cases. 
Statistical analyses were performed using StataSE 12 for Windows (StataCorp LP. 2011. 
Stata Statistical Software: Release 12. College Station, TX, USA) and Microsoft Excel© 
Professional Plus 2010 (Microsoft Corporation, Redmond, WA, USA). 
Results 
Data obtained from primary care registries corresponded to 26,188 admissions from 12,119 
patients with a diagnosis of lung or bronchial cancer between 2011 and 2016. Separately, 
the database for hospitalisation and specialised care included 173,592 entries with lung or 
bronchial cancer as the admission motive that corresponded to 113,574 patients (Table 2). 
Males represented the majority of patients, and were significantly older than female 
patients in both settings (p<0.001). 
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Over 73% of the records included a histological description of the tumour. Only 14.71% of 
the specified diagnoses were of SCLC while 85.29% corresponded to NSCLC (Figure 1A). 
Overall, adenocarcinoma was the predominant tumour typology, with no differences 
observed between males and females. Additionally, tumour location was specified in 
57.51% of secondary care files. Data suggested a predominance of patients with the tumour 
located in the upper lobe of the bronchus or lung (Figure 1B).  
The temporal analysis revealed a minor increase in the number of patients diagnosed in 
primary care centres during the study period, from the 1,549 patients attended in 2011 to 
the 2,087 patients attended in 2016. The percentage of males attended in these centres 
steadily decreased, while the percentage of females increased (p<0.001, 2011 vs. 2016) 
(Figure 2A). On the contrary, the number of patients attended in secondary care remained 
stable over the study period; however, a slight decreasing trend was observed among males, 
compensated by an increase in the percentage of female patients (Figure 2B). 
The principal diagnosis upon hospitalisation (admission motive) was in all cases a lung 
carcinoma, and secondary diagnoses were utilised to perform an analysis of relevant 
comorbid conditions at the hospital level. Metastatic or secondary malignant neoplasms 
were registered in 76.66% of patients with a lung carcinoma (Table 3). The second most 
repeated comorbidity was hypertension, found in 33.57% of patients. A history of tobacco 
use appeared in 25.29% of patients. Respiratory symptoms were common among these 
patients, as respiratory failure and bronchitis, likely to be symptoms of the disease. Chronic 
obstructive pulmonary disease (COPD) was registered in 12.19% of all patients. Other 
registered comorbidities were disorders of lipoid metabolism and diabetes mellitus, 
diagnosed in 23.02% and 21.39% of patients respectively. 
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In-hospital mortality was 22% during the study period. Overall, 82.00% of patients 
deceased were males, averaging 69.06 (SD=10.88) years. Females represented only 22.66% 
of deceased patients, and had a mean of 65.69 (SD=13.27) years. Mortality was 
significantly higher in patients diagnosed with a SCLC, reaching the 29.62% (p<0.001). 
Metastatic and secondary malignant neoplasms were more commonly diagnosed in this 
group and the overall number of malignant neoplasms was superior to the number of 
patients deceased, indicating the presence of multiple tumours per patient. Respiratory 
failure was associated with death in this population. Overall, the number of patients 
deceased during hospitalisation remained stable over the study period.  
The vast majority of hospitalisation records included in the analysis (98.81%) corresponded 
to inpatient care, with a predominance of non-scheduled admissions that summed 64.58% 
vs. 35.42% of scheduled admissions. Only 16% of those were due to readmissions, 
understood as a second admission within a 30-day period following discharge.  
Patients were hospitalised 9.57 days on average, 10.63 days when admissions were due to 
emergencies and 7.63 days in scheduled admissions. Internal medicine was the service to 
discharge 25.44% of the patients, 23.78% were attended by oncology services, 21.24% by 
pneumology and pulmonology services, 18.81% by thoracic surgery services and 4.85% by 
palliative care services. Altogether, imaging techniques were frequently used to diagnose 
these patients, as well as biopsies of distinct organs (Table 4). Chemotherapy was 
administered in 18.21% of all admissions, and lung resection performed in 12.08%.   
Socioeconomic data gathered in primary care centres indicated that 70.90% of the patients 
had an annual rent under the €18,000; 11.81% of the patients were not active or 
unemployed while 74.14% were pensioners. Finally, a direct cost was associated to each 
admission in accordance with the nature of the hospitalisation process and medical 
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procedures utilised. The database registered a direct medical cost of lung cancer that 
reached the €962.6 million solely considering secondary care.  
The mean cost per patient was €8,475, increasing significantly over the study period, from 
€8,364 per patient the year 2011 to €9,164 per patient the year 2016 (p<0.001). 
Interestingly, within the group of patients with an unspecified tumour type, SCC was 
responsible for the highest costs per patient, €9,101 on average (p<0.001), whereas, when 
the total costs incurred by these patients was considered, adenocarcinomas were the 
NSCLC responsible for the largest portion of medical costs (p<0.001) (Figure 3).  
Discussion 
Lung cancer epidemiology has been extensively investigated in Spain, with special 
emphasis in the trends followed during the eighties and nineties when the first measures to 
control tobacco consumption in public buildings were implemented. A clear association 
was observed between these measures and lung cancer incidence, reversing the increasing 
incidence trend observed until 1994 among males aged 65-74 [7]. A more restrictive 
legislation was approved the year 2005 and updated in 2011 including the prohibition of 
smoking in bars and restaurants [20, 21]. This study aimed to analyse tendencies in lung 
cancer occurrence after 2011, to determine the characteristics of the population at risk and 
to provide complementary epidemiologic data to on-going observational studies.  
The number of new lung cancer cases slightly increased in primary care while it remained 
stable in secondary care between 2011 and 2016. The portion of females increased in both 
cases. In addition, females diagnosed with a lung carcinoma were significantly younger 
than males. Previous data gathered between 1996 and 2002 indicates the higher smoking 
prevalence in Spanish girls aged 15–17 years old, accompanied with heavier smoking 
habits [22]; however, it is not clear whether enough time has elapsed to extract definitive 
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conclusions. Likewise, the expected differential incidence of SCLC and NSCLC in males 
and females was not observed herein [9]. The differential trends in incidence in males and 
females have been previously observed, however, geographic and socioeconomic 
differences play an important role [23, 24]. The proportion of SCLC and NSCLC, 15% vs. 
85% was consistent with previous descriptions, as it was the greater prevalence of 
adenocarcinoma [25].  
Hospitalisation records showed the importance of internal medicine services in the 
treatment of lung cancer, together with oncology and pulmonology services, supporting the 
need of establishing protocols that facilitate a multidisciplinary care of the disease, called to 
improve patients’ prognosis [26]. Consequently, the great number of emergency admissions 
found in this patient population could be reduced. 
Regarding patient survival, the database does not permit an analysis of lung cancer 
mortality due to the lack of data on deaths occurred outside of healthcare centres. In-
hospital mortality was 22% over the study period, reaching the 29.62% in patients with 
SCLC, and remained stable between 2011 and 2016. Data gathered in Spain between 1975 
and 1989 showed relative increments in mortality, especially among males, that contrasted 
with the decreasing trends measured in countries as England and Switzerland [27]. In 
general terms, global data indicates a decrease in lung cancer mortality over the past years, 
resulting from the decreasing mortality among males [28]. 
The segregate analysis of patients that died during the hospitalisation provided interesting 
data. Previous studies associated the presence of comorbid conditions in lung cancer 
directly to survival [29]. Herein, several differences appeared between the patients that died 
and the total patient population. The presence of metastatic and secondary malignant 
neoplasms appeared determinant in this pool of patients. On the other hand, the registration 
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of other comorbidities as tobacco smoking appeared low at the hospital level. Preliminary 
results obtained from an observational cohort study taking place in Spain, indicated that up 
to 86% of patients hospitalised due to lung malignant neoplasms could be current or ex-
smokers, which could indicate an incomplete registry of such factors in Spanish hospitals 
[30]. Alcohol consumption has been previously appointed as a factor in lung cancer 
carcinogenesis, however, evidence in never smokers is contradictory [31, 32].  Similarly, 
the diagnosis of diabetes has been previously associated to a worsened prognosis in lung 
cancer patients, an affect that was not observed in this database [33, 34]. Nonetheless, it 
must be taken into account that data registered upon admission may be incomplete. 
In terms of medical costs, evaluations made in the United States measured a mean direct 
medical cost per NSCLC treatment of around €14,000 per patient, with strong variations 
depending on cancer stage [35]. Similarly, calculations in Australia show mean annual 
costs of cancer care of around €2,800 per patient that increase to €31,000 the last year of 
life [36]. Data obtained in different countries by distinct methods is hardly comparable, 
although in all cases delayed diagnoses suppose an important increase in costs. The present 
study shows a small increasing trend in the cost per patient over time that could be 
compensated by the implementation of prevention and early screening measures. 
It is plausible that a number of limitations may have influenced the results of this study. 
The database providing secondary care data is codified with ICD-9 and ICD-10 codes, thus, 
data reliability is subjected to the accuracy of codification achieved at the hospital level. In 
addition, the shift from ICD-9 to ICD-10 between the years 2015 and 2016 should be taken 
into account to interpret quantitative data.  The analysis of secondary conditions was 
limited to those registered upon admission and to secondary care and may not represent 
disease comorbidity. Finally, the analysis of direct medical costs was restricted to 
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secondary care settings and pharmaceutical were not quantifiable via this database. Further 
research should consider all medical costs to increase comparability.  
Conclusions 
Overall lung cancer incidence appeared stable in secondary care centres, yet, given the 
relative increase of female patients, preventive or early detection measures are 
recommended to reverse this trend, which is likely to have an influence in disease costs. In 
addition, a multidisciplinary approach is called to optimise patient journey. The potential 
roles of disease comorbidities in lung cancer prognosis should be further explored. 
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Table 1. ICD-9-CM, ICD-10-CM and ICD-O-3 codes used to identify lung cancer 
diagnoses and classify tumours.  
Setting and coding system Years Codes Description 
Diagnoses and tumour 
location 
- - - 
Primary care (ICPC-2) 2011-2015 R84 
Malignant neoplasm of 
bronchus/lung 





Malignant neoplasm of 
bronchus and lung 
Secondary care (ICD-10-
CM; ICD-O-3) 
2016 C34.0–C34.92  
Malignant neoplasm of 
bronchus and lung 
Tumour type  - - - 




Large cell carcinoma; Small 

















Table 2. Patient descriptive parameters and tumour classification according to ICD-9-
CM and ICD-10-CM. 
Setting N % of patients Age (SD) 
Primary care centres 12,119 - 68.04 (12.34) 
   Males 9,360 77.23 68.97 (11.52) 
   Females 2,759 22.77 64.89 (14.35) 
Secondary care centres 113,574 - 67.44 (11.25) 
   Males 90,389 79.59 68.16 (10.71) 



















Table 3. Secondary conditions registered in more than 10% of all patients and of 
deceased patients. 
Secondary diagnoses 
% of all 
patients 




Secondary or metastatic malignant neoplasm 76.66 104.25 2.02 (1.98-2.06) 
   Malignant neoplasm of bone  16.50 28.20 2.12 (2.06-2.19) 
   Malignant neoplasm of respiratory system 15.55 24.14 1.80 (1.74-1.85) 
   Malignant neoplasm of the liver 12.46 22.61 2.39 (2.31-2.47) 
Unspecified essential hypertension 33.57 24.90 0.86 (0.84-0.89) 
History or current tobacco use  25.29 18.17 0.83 (0.81-0.85) 
Disorder of lipoid metabolism 23.02 15.91 0.75 (0.73-0.78) 
Respiratory failure 15.21 20.29 3.52 (3.41-3.64) 
Diabetes mellitus 21.39 48.95 0.99 (0.96-1.02) 
Bronchitis 10.05 10.50 1.06 (1.02-1.11) 
Chronic obstructive pulmonary disease 12.19 9.11 0.87 (0.84-0.91) 
















Table 4. Medical procedures registered in patients with lung cancer.   
Medical procedures % of admissions 
Imaging - 
    Thorax tomography 38.95 
    Abdomen tomography 18.51 
    Thorax radiography 21.69 
Biopsy 39.77 
    Lung and bronchus 12.52 
    Lymph nodes 3.98 
Chemotherapy 18.21 
Radiotherapy   3.15 
Surgery  - 
    Lung resection or excision 12.08 
Respiratory therapy 22.96 
    Oxygen enrichment 10.61 
    Mechanical ventilation 1.62 
















Figure 1. Percentage of patients per tumour typology (A) and location (B). 
 
Figure 2. Percentage of male and female patients admitted with lung cancer in 






Figure 3. Annual direct medical cost estimated for the group of patients with a 
specified tumour. 
 
 
